Key regions: United Kingdom, Canada, Japan, Europe, China
Switzerland, a country known for its natural beauty and picturesque landscapes, has been witnessing a significant growth in the dermatological drugs market.
Customer preferences: Swiss customers have been showing a growing interest in dermatological drugs due to the increasing prevalence of skin diseases in the country. According to a recent study, around 20% of the Swiss population suffers from skin diseases such as eczema, psoriasis, and acne. This has led to a rise in demand for dermatological drugs, including topical creams, ointments, and gels.
Trends in the market: One of the major trends in the Swiss dermatological drugs market is the growing popularity of natural and herbal products. Swiss customers are increasingly looking for products that are free from harmful chemicals and have minimal side effects. This has led to a rise in demand for natural and herbal dermatological drugs, which are perceived as safer and more effective than synthetic drugs.Another trend in the Swiss dermatological drugs market is the increasing use of biologics for the treatment of skin diseases. Biologics are a new class of drugs that are derived from living organisms and are highly effective in treating skin diseases such as psoriasis and eczema. The use of biologics is expected to increase in the coming years as more patients opt for these drugs due to their high efficacy and minimal side effects.
Local special circumstances: Switzerland is home to several pharmaceutical companies that specialize in dermatological drugs. These companies have been investing heavily in research and development to develop new and innovative dermatological drugs that cater to the needs of Swiss customers. This has led to a rise in the availability of advanced dermatological drugs in the country, which has in turn boosted the growth of the market.
Underlying macroeconomic factors: The Swiss economy has been performing well in recent years, with a stable GDP growth rate and low unemployment rate. This has led to an increase in disposable income among Swiss customers, which has, in turn, led to a rise in demand for dermatological drugs. Additionally, the Swiss healthcare system is one of the best in the world, with a high level of healthcare coverage and access to advanced medical treatments. This has made it easier for Swiss customers to access dermatological drugs and has contributed to the growth of the market.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
